Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant olaparib in platinum-sensitive recurrent high-grade serous ovarian cancer
2016-002573-35Phase 2Unknown
- Sponsor
- University Health Network
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by University Health Network. Status: unknown.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2016-002573-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002573-35.